DOWNLOAD Proposed $1.0 Million Convertible Debenture and Warrant Financing andConcurrent Common Share Private Placement Up to $1.0 MillionIntended to Support Near-Term Operations Vancouver, British Columbia – February 20, 2026 – Rakovina Therapeutics Inc. (TSX-V:...
DOWNLOAD Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field. Expanded Opportunity:...
Be in the know with the Rakovina Therapeutics monthly investor newsletter! Each month you’ll find out what’s going on with the company and be the first to receive news release straight to your inbox.
Recent Comments